Division of Amgen Inc.
Latest From Micromet Inc.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.
Takeda indicates to analysts that it is warming to idea of buying Shire, but do Pfizer or Amgen make greater sense to acquire the rare disease specialist?
TCR2 Therapeutics raised a $125m Series B round to take two T-cell receptor (TCR)-based therapies into the clinic for solid tumors. The company's technology platform overcomes HLA-matching issues to make TCR-based treatments available to more patients.
- Large Molecule
- Therapeutic Areas
- Micromet AG
- North America
- Parent & Subsidiaries
- Amgen Inc.
- Senior Management
Patrick A Baeuerle, PhD, SVP, CSO
Jan Fagerberg, MD, PhD, SVP, CMO
Joseph Lobacki, Chief Commercial Officer
- Contact Info
Phone: (240) 752-1420
9201 Corp. Blvd.
Rockville, MD 20850